Global Immunotherapy Drugs Market Size Study, by Type of Drugs (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Others) by Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Others) by End-Use (Hospitals, Clinics, Others) by Regional Forecasts 2017-2025
-
Product Code:
RP-ID-10013462 -
Published Date:
21 Oct 2022 -
Region:
Global
-
Pages:
180 -
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-14
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
Global Immunotherapy Drugs Market valued approximately USD 108.5 billion in 2016 is anticipated to grow with a healthy growth rate of more than 14.0% over the forecast period 2017-2025. Faster drug approval processes, rising prevalence of life style-oriented diseases, and rising adoption of targeted therapies are the primary growth drivers for global immunotherapy drugs market. However, the market growth is restricted by the high cost of immunotherapy treatment.
Global Immunotherapy market is segmented by type of drugs, therapy area and end-use. Based on therapy area the market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these, currently the market is dominated by cancer segment which is anticipated to account for 33% revenue share in 2016. The cancer segment will continue to dominate over the forecast period and is also anticipated to register the highest growth over the forecast period. Increasing prevalence of cancer and rising adoption of immunotherapy for cancer treatment is driving the market growth.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type of Drugs:
 Monoclonal Antibodies
 Adult Vaccines
o Preventive Vaccines
o Therapeutic Vaccines
 Checkpoint Inhibitors
 Interferons Alpha & Beta
 Interleukins
 Other Drugs
By Therapy Area:
 Cancer
 Autoimmune & Inflammatory Diseases
 Infectious Diseases
 Other Therapy Area
By End-Use:
 Hospitals
 Clinics
 Other End Users
By Regions:
 North America
o U.S.
o Canada
 Europe
o UK
o Germany
 Asia Pacific
o China
o India
o Japan
 Latin America
o Brazil
o Mexico
 Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2015
Base year - 2016
Forecast period - 2017 to 2025
Some of the key manufacturers involved in the market F.Hoffmann, Merck & Co., Inc., Novartis International AG, Johnson & Johnson (A Parent Company of Jannssen Biotech, Inc.), Glaxosmithkline PLC, Amgen Inc., Abbvie, Amstrazeneca, Bristol-Mysers Squibb, ELI Lilly & Company Frequent cross industry partnerships are leading to market consolidation.
Target Audience of the Global Immunotherapy Drugs Market in Market Study:
 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors
Geography Analysis:
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
.
Please enter your personal details below
Novartis International AG
Johnson & Johnson (A Parent Company of Jannssen Biotech, Inc.)
Glaxosmithkline PLC
Amgen Inc.
Abbvie
Amstrazeneca
Bristol-Mysers Squibb
ELI Lilly & Company